ClinicalTrials.gg
RecruitingNCT06091774ERKHAUpdated Mar 6, 2024

Clinical Study for the Investigation and Validation of a Therapy Procedure for the Adjustment of Risk Factors in Patients With Coronary Heart Disease by Means of Digital Therapy Control

An observational study in Coronary Artery Disease, Cardiovascular Diseases and Coronary Heart Disease, sponsored by iATROS GmbH. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-06.

Sponsored by iATROS GmbH · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 365 studies in Coronary Artery Disease with a site in Germany — 46 open to participants now, 71 under way, 3 of them phase 3. Coronary Artery Disease · Germany.

Planned enrollment
43rd of 117
1,000 · median 550
Started
2023
with 14 others
Observational
117 of 365
22 open now
Primary completion
2025-04
later than 14 of 70 live
Registered
342nd of 365
by date

Among the 365 studies in Coronary Artery Disease with a site in Germany, this one is the 43rd largest by planned enrollment of the 117 observational ones that give a count, is one of 15 that started in 2023, is one of 117 observational ones, reaches primary completion later than 14 of the 70 other live ones, and was the 342nd registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

46 of the 365 studies in Coronary Artery Disease with a site in Germany are open now. Recruiting first, the newest first:

40 more — sign in →

All 46 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Coronary Artery Disease with a site in Germany, or all of them as a file.
02

Study summary

This study will test a controlled investigation of the efficacy and effectiveness of iATROS digital therapy management for risk factor adjustment in patients with coronary heart disease (CHD).

Read the detailed description

The purpose of this study is to determine the efficacy and effectiveness of iATROS digital therapy management for risk factor adjustment in patients with coronary heart disease compared to the medical standard of care.

In addition, data will be provided to investigate the functionality of the rule engine in the treatment of CHD patients and insights will be gained for the further development of this component of the iATROS platform for the digital and intelligent treatment of patients.

Furthermore, the use of digital everyday products (smartphones) in secondary prevention and therapy management of CHD patients will be considered.

03

Conditions studied

  • Coronary Artery Disease
  • Cardiovascular Diseases
  • Coronary Heart Disease
  • Ischemic Heart Disease

Keywords

  • eHealth
  • cardiology
  • coronary artery disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All adult (≥ 18 years) patients with a diagnosis of coronary artery disease at study inclusion AND one of the following conditions: Diagnosis of STEMI/NSTEMI , OR they have had coronary intervention (eg, stent, angioplasty, or bypass surgery) or a similar formulation, are eligible to participate in the study as long as they meet the inclusion/exclusion criteria and are insured by the cooperating insurers.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years
  • Patients diagnosed with ischemic heart disease according to ICD I20 to I25 who also have at least one of the following:

    1. inpatient stay with acute STEMI/NSTEMI or historic STEMI/NSTEMI; and/or
    2. Coronary stent implantation, angioplasty or bypass surgery that has taken place.
  • Ownership and use of a smartphone that allows installation and use of "iATROS," where "use" requires having the physical and mental ability to use and apply the iATROS app.
  • Insured with the cooperating insurances

Exclusion criteria

Exclusion Criteria:

  • No use of a smartphone
  • Lack of the linguistic, physical and mental abilities necessary to use the iATROS app, or to use so-called "apps" on a smartphone or tablet in general.
  • Absolute : Any disease associated with a reduced of less than 2 years; Any disease/condition that limits participation in the program; Pregnant or breast feeding patients; Patients with advanced dementia
  • Existing participation and enrollment in an iATROS health program.
  • Participation in another clinical trial if participation results in complications with compliance, measures to be performed, bias of results, or status of treatment according to the current standard of care.
  • Comorbidities or the presence of another physical condition that complicates the setting of the clinical target parameters sought in the study (i.e., if, due to the patient's individual situation, a different value would have to be issued as the target value for a clinical parameter to be classified as healthy).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group with the medical device "iATROS"

    Patients are subsequently assigned to one of the two groups in a 1:1 randomization. The treatment to be carried out in the intervention group is the use of the therapy control for the treatment of CHD, which is played out via the iATROS medical device. At the start of the digital treatment, the patients receive suitable measuring devices for recording their vital parameters in the home environment. With the completion of the visit in month 9, the active phase of the study has ended. Patients will now use the iATROS medical device for another 9 months, after which the stability of the intervention effects will be determined.

    Device: CHD therapy through iATROS medical device

  • Group without the medical device "iATROS"

    All patients in the control group will receive standard-of-care treatment in the 9 months after randomization. There will be no further intervention during this phase. Similarly, treatment is not influenced or restricted in terms of free choice of medical care or medical treatment. Subsequently, they also receive access to the iATROS medical device. Patients will receive suitable measuring devices for recording their vital parameters in the home environment. The effects of the intervention will be recorded after 9 months.

Interventions

  • DeviceCHD therapy through iATROS medical device

    The intervention to be carried out in the treatment group is the use of the therapy control for the treatment of CHD played out via the iATROS medicine product. Patients will receive a suitable and medical device certified measuring device for recording vital parameters. The iATROS app is downloaded to the patient's smartphone and the app is activated by entering a code that identifies the user as a participant in the study. When using the app for the first time, the patient is guided through the first steps of using the app and asked to transfer his or her health data to the app. The therapy control by means of the medication product takes place over the entire duration of the study.

06

What researchers measure

Primary outcomes

  1. Proportion of patients in target range of LDL or blood pressure

    Proportion of patients per study arm in percent with adjusted LDL cholesterol in the blood of \< 55 mg/dl (\< 1.4 mmol/l) and/or adjusted blood pressure according to ESC guideline (≤130 mmHg systolic or ≤140 mmHg systolic for age \> 70 years).

    Time frame: 9 months

Secondary outcomes

  1. Absolute LDL reduction after 9 months in patients with known LDL levels at inclusion (not older than 12 months at study inclusion) and no medication adjustment within the last 12 months prior to study inclusion.

    Comparison of the mean value of the absolute reduction between the treatment and control group of this patient population with regard to statistically significant differences. Furthermore, intra-group comparison of this patient population per study arm to determine statistically significant effects with regard to LDL reduction by treatment with iATROS over 9 months.

    Time frame: 9 months

  2. Assessment of stability: Comparison of LDL levels after 18 months in patients with known LDL levels

    Comparison of medical parameter LDL (available through standard-of-care treatment) between the two study arms after 18 months study duration.

    Time frame: 18 months

  3. Assessment of stability: Comparison of blood pressure after 18 months

    Comparison of blood pressure values (available through standard-of-care measurements) between the two study arms after 18 months study duration.

    Time frame: 18 months

  4. In patients with diabetes: target blood HbA1c level of ≤ 7% or ≤ 53mmol/mol after 9 months.

    Comparison of the proportion of patients per study arm in percent in the HbA1c target range with regard to statistically significant differences. In addition to an intergroup comparison, an intragroup comparison per study arm will be performed.

    Time frame: 9 months

  5. Assessment of stability in patients with diabetes: Comparison of blood HbA1c levels after 18 months.

    Comparison of medical parameter HbA1c (available through standard-of-care treatment) between the two study arms after 18 months study duration.

    Time frame: 18 months

  6. In patients with diabetes: absolute reduction in blood HbA1c level after 9 months.

    Comparison of the mean absolute reduction in HbA1 levels between the treatment and control groups for statistically significant differences in patients with history of HbA1c levels at inclusion. Furthermore, intragroup comparison per study arm to determine, whether treatment with iATROS has a statistically significant effect on the reduction of HbA1c levels over 9 months.

    Time frame: 9 months

  7. In patients with obesity: absolute BMI reduction after 9 months.

    Comparison of the mean value of the absolute BMI reduction and the absolute weight reduction in \[kg\] with regard to the statistical significance of the absolute change between all patients in the treatment and control group. In addition to an intergroup comparison, an intragroup comparison per study arm will be performed.

    Time frame: 9 months

  8. Assessment of stability in patients with obesity: Comparison of BMI changes after 18 months.

    Comparison of BMI values (available through standard-of-care measurement of weight and height which will be combined to report BMI in kg/m\^2) between the two study arms after 18 months study duration.

    Time frame: 18 months

  9. Absolute BMI reduction in patients with initial BMI > 30kg/m2 after 9 months.

    Comparison of the mean value of the absolute BMI reduction of this patient collective as well as the mean absolute weight reduction in \[kg\] with regard to statistical significance of the absolute change between the treatment and the control group. In addition to an intergroup comparison, an intragroup comparison per study arm will be performed.

    Time frame: 9 months

  10. In patients with obesity: percentage reduction in body mass index (BMI) after 9 months, which should fall within the target range below 25 kg/m2 as best as possible according to guideline recommendations.

    Comparison of the mean value of the percentage BMI reduction between the treatment and control groups with regard to statistical significance. In addition, a comparison with the predefined target value is to be used to calculate which proportion of the intervention and control groups falls within this target range in \[%\] before the study period and after 9 months. In addition to an intragroup comparison, an intragroup comparison per study arm will be performed.

    Time frame: 9 months

  11. For patients with current nicotine abuse: determination of/review of smoking cessation after 9 months.

    Query of smoking status and pack years per patient. Comparison of the percentage per study arm, who no longer define themselves as "smokers" and the percentage of patients who have defined themselves as "ex-smokers" for \>6 months. Comparison of study arms and intragroup comparison 9 months after inclusion. Determination of smoking status using the Fagerström test for nicotine dependence (FTND).

    Time frame: 9 months

  12. Assessment of stability for patients with current nicotine abuse: determination of/review of smoking cessation after 18 months.

    Comparison of Fagerström test for nicotine dependence (FTND) scores between the two study arms after 18 months study duration.

    Time frame: 18 months

  13. Improving health literacy

    The study will examine whether an improvement in health literacy can be measured after 9 and 18 months when using digital therapy management via iATROS. The Rasch-scaled short form of the European Health Literacy Survey (HLS-EU-Q16) questionnaire comprises 16 questions that are rated on a 4-level scale, with the answer options focussing on the respective difficulty (very easy, fairly easy, fairly difficult, very difficult). The four answer options are dichotomised, whereby the two categories "very easy" and "fairly easy" were assigned a value of 1 and the two remaining categories a value of 0. Based on the sums achieved, the health literacy of the patients is finally categorised as "insufficient" (sum 0-8), "problematic" (sum 9-12) and "sufficient" (sum 13-16).Since the questionnaires are submitted in the treatment group and the control group both at baseline and after 9 and 18 months, respectively, an intra-group comparison as well as an inter-group comparison is possible.

    Time frame: 9 months and 18 months

  14. Assessment of stability: Improving health literacy

    Comparison of the European Health Literacy Survey (HLS-EU-Q16) scores between the two study arms after 18 months study duration.

    Time frame: 18 months

  15. Improving patient sovereignty

    The study will examine whether the use of iATROS results in an increase in patient sovereignty after the treatment period of 9 and also 18 months. In order to measure this, a short-form of the Patient Activation Measure (PAM-13) will be used. The results are divided into different categories by quantitatively evaluating the results of the questions answered in a four-point Likert scale (not true, hardly true, rather true, exactly true). The total score results from the answers to the individual questions after standardization and is divided into four levels: Level 1 (lack of belief that activation is important, ≤47 points), Level 2 (lack of knowledge and confidence to take action, 47.1-55.1 points), Level 3 (beginning to take action, 55.2-67.0 points) and Level 4 (taking action, ≥67 points). The measurement of PAM-13 at the beginning of the study and after 9 and 18 months allows an intragroup and intergroup comparison.

    Time frame: 9 months and 18 months

  16. Assessment of stability: Improving patient sovereignty

    Comparison of the Patient Activation Measure (PAM-13) scores between the two study arms after 18 months study duration.

    Time frame: 18 months

07

Study locations

1 of 1 sites recruiting
  • Klinikum der Ludwig-Maximilians-Universität München (Klinikum der Universität München), Medizinische Klinik und Poliklinik I
    Munich, Bayern 81377, Germany
    Recruiting
    • Julia Brust · ContactJulia.Brust@med.uni-muenchen.de · +49 89 4400 72371
    • Moritz Sinner, PD Dr. med. · Principal investigator
    • Stefan Kääb, Prof.Dr.med. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Apr 2025, 18 months after the start.

Of 125 industry-sponsored observational studies under Coronary Artery Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 18 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2023
First posted
Oct 19, 2023
StartActual
Oct 5, 2023
Primary completionEst.
Apr 2025
CompletionEst.
Oct 2026
Last update
Mar 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06091774
Lead sponsor
iATROS GmbH
Responsible party
Sponsor
First posted
Oct 19, 2023
Start date
Oct 5, 2023
Primary completion
Apr 2025 (estimated)
Completion
Oct 2026 (estimated)
Last update
Mar 6, 2024

Study contacts

Paul Weyh, M. Sc.
Contact
paul.weyh@i-atros.com
+49 176 856 23 142
Georges von Degenfeld, Dr. med.
Contact
georges.degenfeld@i-atros.com
+49 89 - 95879243
Moritz Sinner, PD Dr. med
principal investigator · Medizinische Klinik I und Poliklinik LMU Klinikum Campus Großhadern
Stefan Kääb, Prof.Dr.med.
principal investigator · Medizinische Klinik I und Poliklinik LMU Klinikum Campus Großhadern

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion